Cranial and extracranial giant cell arteritis do not exhibit differences in the IL6 -174 G/C gene polymorphism.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 27 09 2022
accepted: 16 11 2022
medline: 20 4 2023
pubmed: 14 3 2023
entrez: 13 3 2023
Statut: ppublish

Résumé

Since interleukin-6 (IL-6) is a pivotal proinflammatory cytokine implicated in the pathogenesis of giant cell arteritis (GCA), we aimed to determine the potential association of the functional IL6 -174 G/C polymorphism with GCA as well as if the single base change variation at the promoter region in the human IL-6 gene may account for differences in the clinical spectrum of GCA between cranial and extracranial large vessel vasculitis (LVV)-GCA. The IL6 -174 G/C polymorphism (rs1800795) was genotyped in 191 patients with biopsy-proven GCA who had typical cranial manifestations of the disease, 109 patients with extracranial LVV-GCA, without cranial ischaemic manifestations of GCA, and 877 ethnically matched unaffected controls. A comparative study was carried out between patients with cranial and extracranial LVV-GCA and controls. No significant differences in genotype and allele frequencies of IL6 -174 G/C polymorphism were found between the whole cohort of GCA patients and healthy controls. It was also the case when cranial and extracranial LVV-GCA were compared or when each of these subgroups was compared to controls. Moreover, no significant results in genotype and allele frequencies of IL6 -174 G/C polymorphism were disclosed when the whole cohort of GCA patients were stratified according to the presence of polymyalgia rheumatica, severe ischaemic manifestations, including permanent visual loss and peripheral arteriopathy, and HLA-DRB1*04:01 status. Our results show that the IL6 -174 G/C polymorphism does not influence the phenotypic expression of GCA.

Identifiants

pubmed: 36912345
pii: 19224
doi: 10.55563/clinexprheumatol/cbjnmo
doi:

Substances chimiques

Interleukin-6 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

910-915

Auteurs

Fernanda Genre (F)

Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain.

Diana Prieto-Peña (D)

Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Verónica Pulito-Cueto (V)

Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain.

Javier Gonzalo Ocejo-Vinyals (JG)

Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Belén Atienza-Mateo (B)

Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Alejandro Muñoz Jiménez (A)

Department of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Francisco Ortiz-Sanjuán (F)

Department of Rheumatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Susana Romero-Yuste (S)

Department of Rheumatology, Complejo Hospitalario Universitario Pontevedra, Spain.

Clara Moriano (C)

Department of Rheumatology, Complejo Asistencial Universitario de León, Spain.

Eva Galíndez-Agirregoikoa (E)

Department of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain.

Itziar Calvo (I)

Department of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain.

Norberto Ortego-Centeno (N)

Department of Internal Medicine, University of Granada, Spain.

Noelia Álvarez-Rivas (N)

Department of Rheumatology, Hospital Universitario San Agustín, Avilés, Spain.

José A Miranda-Filloy (JA)

Division of Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain.

Irene Llorente (I)

Department of Rheumatology, Hospital Universitario de la Princesa, IIS-Princesa, Cátedra EPID Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain.

Ricardo Blanco (R)

Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Oreste Gualillo (O)

Health Research Institute of Santiago, Santiago de Compostela; and The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain.

Javier Martín (J)

Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Spain.

Santos Castañeda (S)

Department of Rheumatology, Hospital Universitario de la Princesa, IIS-Princesa, Cátedra EPID Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain.

Raquel López-Mejías (R)

Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain.

Sara Remuzgo-Martínez (S)

Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain.

Miguel A González-Gay (MA)

Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander; Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander; School of Medicine, Universidad de Cantabria, Santander, Spain; and Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. miguelaggay@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH